Vermont, New York, New Hampshire sue to stop 23andMe sale
23andMe is in bankruptcy protection. The company is known for its direct-to-consumer genetic testing services, allowing people to obtain information about their ancestry and potential health conditions.
NYS Senate passes Medical Aid in Dying Act
Bio-tech company Regeneron Pharmaceuticals requested the court's approval to buy the firm for $256 million, but the states say DNA samples of about 15 million previous customers are too sensitive to allow the transaction without each person giving their informed consent.
'Genetic information is some of the most sensitive information a company can hold about a person,' said Vermont Attorney General Charity Clark. 'It's incredibly personal and forever unchangeable.
'Vermonters' genetic information shouldn't be up for sale without their consent. I am taking action to make sure that Vermonters have the right to decide what happens with their genetic information.'
Two found with 'over 100 glassine bags' of fentanyl in Vt.
The court has appointed an independent official to examine the proposed sale and its impact on consumer privacy.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13-08-2025
- Yahoo
[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of US Personalized Medicine Market size & share revenue was valued at approximately USD 56.37 Billion in 2024 and is expected to reach USD 66.13 Billion in 2025 and is expected to reach around USD 252.93 Billion by 2034, at a CAGR of 17.32% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Illumina Inc., Precision Biologics, Danaher Corporation (Cepheid Inc.), GE HealthCare, Celera Diagnostics LLC, Decode Genetics Inc., Exact Sciences Corporation, IBM Corporation, Exagen Inc., Biogen, QIAGEN, Genentech Inc., 23andMe Inc., Asuragen Inc and others. Austin, TX, USA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'US Personalized Medicine Market Size, Trends and Insights By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Nutrition and Wellness), By Application (Oncology, CNS, Immunology, Respiratory, Liver, Rheumatology), By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, Genetics, Liquid Biopsy, Others (Predictive Modeling, Imaging)), By End-user (Hospitals, Diagnostic Centers, Research & Academic Institutes), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034' in its research database.'According to the latest research study, the demand of US Personalized Medicine Market size & share was valued at approximately USD 56.37 Billion in 2024 and is expected to reach USD 66.13 Billion in 2025 and is expected to reach a value of around USD 252.93 Billion by 2034, at a compound annual growth rate (CAGR) of about 17.32% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the US Personalized Medicine Market @ Overview As per the industry experts at CMI, the U.S. personalized medicine market is poised to witness a whopping CAGR in the forecast period. This could be attributed to genomic advancements such as next-generation sequencing that facilitate more accurate diagnostics and targeted therapies. The patients are asking for more customized approaches toward healthcare, thereby resulting in higher adoption of personalized medicine. Rise in incidences of chronic diseases such as cardiovascular diseases, cancer, and diabetes is accelerating the requirement of more personalized and effective treatment strategies. Conducive government policies coupled with raised funding for research and development activities are driving innovation. Key Trends & Drivers Technological Advancements and Higher Healthcare Spending to Spell Growth: Continuous advancements in data analytics, genomics, and bioinformatics are pushing the U.S. personalized medicine market forward. technologies such as CRISPR, NGS, and AI are transformingtreatment plans and diagnostics and making them more targeted as well as individualized. This innovation translates into patients' better understanding and customizes the treatment with better results. Also, as healthcare spending increases, the government as well as private agencies continue spending more dollars on the new technologies pertaining to modern medicine as mentioned above. Request a Customized Copy of the US Personalized Medicine Market Report @ Rise in Incidences of Chronic Diseases to Catalyze the U.S. Personalized Medicine Market: Chronic ailments cover conditions such as diabetes, cancer, and cardiovascular ailments. Personalized medicines are capable of being more effective in comparison with conventional types of treatment as they end up targeting the molecular and genetic basis of the conditions they address. Report Scope Feature of the Report Details Market Size in 2025 USD 66.13 Billion Projected Market Size in 2034 USD 252.93 Billion Market Size in 2024 USD 56.37 Billion CAGR Growth Rate 17.32% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Product, Application, Technology, End-user and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Country Scope US Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the US Personalized Medicine report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the US Personalized Medicine report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the US Personalized Medicine Market Report @ SWOT Analysis Strengths: Genomic medicine is getting included in clinical practice. It is playing a vital role in diagnosing as well as treating the disease, thereby offering precise, individualized treatments providing better outcomes. Also, institutions are sharing data concerning clinical background, genetic information, and lifestyles across the providers, which facilitates the provision of more extensive and individualized treatment options, thereby helping to release new drugs in a faster way. Weaknesses: Tailored treatments such as sequencing, genetic tests, and targeted medications are costlier in comparison with conventional treatments. This factor does act as a substantial barrier to healthcare systems and insurance firms. Also, handling sensitive data does raise legal and ethical challenges pertaining to data privacy and security. These are some of the threats to the U.S. personalized medicine market. Opportunities: Amalgamating personalized medicine with digital health technologies such as remote monitoring and wearable devices is anticipated to improve patient engagement as well as treatment outcomes. Personalized medicine can also help in the identification of disease risks and promotion of preventive measures. Strategic partnerships amongst research organizations, academic institutions, and industry players have the ability to accelerate the adoption and development of personalized medicine. Threats: Lengthy processes of approvals and complicated regulatory requirements for personalized medicine products are likely to delay market access. The market players are bound to lose interest by the time the entire course of treatment or drugs gets approved and goes live. These are the major threats to the U.S. personalized medicine market. Request a Customized Copy of the US Personalized Medicine Market Report @ Key questions answered in this report: What is the size of the US Personalized Medicine market and what is its expected growth rate? What are the primary driving factors that push the US Personalized Medicine market forward? What are the US Personalized Medicine Industry's top companies? What are the different categories that the US Personalized Medicine Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the US Personalized Medicine market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium US Personalized Medicine Research Report | Fast Delivery Available - [220+ Pages] @ Key Developments The US personalized medicine market is witnessing a significant organic and inorganic expansion. Some of the key developments include – In May 2025, the scientists based in Philadelphia officiated a successful treatment for one of the rare genetic disorders in a nine-month-old baby using personalized CRISPR gene editing therapy. In January 2024, The US state of California announced that it would witness establishment of precision medicine center as the outcome of collaboration amongst the city of Bakersfield, the Kern Venture Group, and BIOS Health. The facility is bound to operate as a central location for R&D and brain clinical trials that use BIOS' adaptive dosage technology. In March 2023, Seagen announced that Pfizer acquired it for USD 229 in cash per Seagen share, totaling to USD 43 Billion enterprise value. Request a Customized Copy of the US Personalized Medicine Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detail Information: support@ Browse the full 'US Personalized Medicine Market Size, Trends and Insights By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Nutrition and Wellness), By Application (Oncology, CNS, Immunology, Respiratory, Liver, Rheumatology), By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, Genetics, Liquid Biopsy, Others (Predictive Modeling, Imaging)), By End-user (Hospitals, Diagnostic Centers, Research & Academic Institutes), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034' Report at of the prominent players in the US Personalized Medicine Market: Illumina Inc. Precision Biologics Danaher Corporation (Cepheid Inc.) GE HealthCare Celera Diagnostics LLC Decode Genetics Inc. Exact Sciences Corporation IBM Corporation Exagen Inc. Biogen QIAGEN Genentech Inc. 23andMe Inc. Asuragen Inc. Others Click Here to Access a Free Sample Report of the US Personalized Medicine Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: Induced Pluripotent Stem Cell (iPSC) Market: Induced Pluripotent Stem Cell (iPSC) Market Size, Trends and Insights By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Others), By Application (Drug Development, Tissue Engineering & Regenerative Medicine, Disease Modelling, Toxicology Research), By End-Use (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Fabry Disease Treatment Market: Fabry Disease Treatment Market Size, Trends and Insights By Treatment (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), Others), By Route of Administration (Intravenous Route, Oral Route), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Elastomeric Infusions Pumps Market: Elastomeric Infusions Pumps Market Size, Trends and Insights By Product (Variable Rate, Continuous Rate), By Application (Antibiotic/Antiviral Therapy, Chemotherapy, Pain Management, Others), By End-Use (Ambulatory Surgical Centers, Hospitals, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Duchenne Muscular Dystrophy Drugs Market: Duchenne Muscular Dystrophy Drugs Market Size, Trends and Insights By Drug Type (Exon skipping drugs, Corticosteroids, Gene therapy, Other drug types), By Route of Administration (Oral, Injectable), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Digital Microscopes Market: Digital Microscopes Market Size, Trends and Insights By Product Type (Digital Biological Microscopes, Electron Microscope, Digital Surgical Microscopes, Others (Digital Inspection Camera, and Others)), By Modality (Desktop Digital Microscope, Portable Digital Microscope), By Connectivity (Wired Digital Microscope, Wireless Digital Microscope), By Application (Research & Development, Life Science, Medical Diagnostics, Forensic Testing), By End User (Hospitals, Clinics, Biopharmaceutical Companies, Academic Research Institute, Others (Forensic and Pathology Laboratory)), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Adult Day Care Services Market: Adult Day Care Services Market Size, Trends and Insights By Services (Adult Social Day Services, Adult Day Healthcare Services, Specialized Day Care Services), By Service Provider (Private, Public), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Synthetic Blood Substitutes and Blood Product Market: Synthetic Blood Substitutes and Blood Product Market Size, Trends and Insights By Source (Human Blood, Animal Blood, Synthetic Polymers, Stem Cells, Others), By Type (Perfluorocarbon Based Product (PFC), Haemoglobin Based Oxygen Carrier, Synthetic Platelet, Recombinant Factor, Blood Expander), By Installation Type (Cardiovascular Diseases, Anaemia, Organ Transplant, Injury and Trauma, Others), By End-User (Hospitals and Clinics, Blood Banks, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Dental Prosthetics Market: Dental Prosthetics Market Size, Trends and Insights By Type (Crowns, Bridges, Abutments, Dentures, Others), By End-User (Solo Practices, DSO/Group Practices, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 The US Personalized Medicine Market is segmented as follows: By Product Personalized Medicine Diagnostics Personalized Medicine Therapeutics Personalized Nutrition and Wellness By Application Oncology CNS Immunology Respiratory Liver Rheumatology By Technology Big Data Analytics Artificial Intelligence Bioinformatics Gene Sequencing Drug Discovery Companion Diagnostics Genetics Liquid Biopsy Others (Predictive Modeling, Imaging) By End-user Hospitals Diagnostic Centers Research & Academic Institutes Click Here to Get a Free Sample Report of the US Personalized Medicine Market @ This US Personalized Medicine Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Key Players in This US Personalized Medicine Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Market Status of the US Personalized Medicine Market? What Was the Capacity, Production Value, Cost and PROFIT of the US Personalized Medicine Market? What Is the Current Market Status of the US Personalized Medicine Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of US Personalized Medicine Market by Considering Applications and Types? What Are Projections of the US Personalized Medicine Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is US Personalized Medicine Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On US Personalized Medicine Industry? What are Macroeconomic Environment Analysis Results? What Are Macroeconomic Environment Development Trends? What Are Market Dynamics of US Personalized Medicine Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for US Personalized Medicine Industry? Click Here to Access a Free Sample Report of the US Personalized Medicine Market @ Reasons to Purchase US Personalized Medicine Market Report US Personalized Medicine Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. US Personalized Medicine Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. US Personalized Medicine Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. US Personalized Medicine Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the US Personalized Medicine market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium US Personalized Medicine Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide US Personalized Medicine market analysis. The competitive environment of current and potential participants in the US Personalized Medicine market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide US Personalized Medicine market should find this report useful. The research will be useful to all market participants in the US Personalized Medicine industry. Managers in the US Personalized Medicine sector are interested in publishing up-to-date and projected data about the worldwide US Personalized Medicine market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in US Personalized Medicine products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the US Personalized Medicine Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium US Personalized Medicine Research Report | Fast Delivery Available - [220+ Pages] @ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-07-2025
- Yahoo
Regeneron Pharmaceuticals, Inc. (REGN) Acquires 23andMe Assets in $256M Deal
We recently compiled a list of Regeneron Pharmaceuticals, Inc. tops our list for being one of the most undervalued healthcare stocks. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most undervalued stocks. It is a leading American biotech company specializing in treatments for serious diseases across ophthalmology, immunology, oncology, and rare conditions. The company is known for integrating genetics and technology into its drug discovery efforts and continues to grow through internal innovation and strategic acquisitions. In a major move, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is acquiring most of 23andMe's assets for $256 million, including its personal genome service, research services, biobank, and associated data. This will expand the business's access to genetic information from 15 million individuals (with 80% consenting to research use), enhancing its existing warehouse of 3 million anonymized samples. The acquisition significantly boosts Regeneron's capabilities in genetics-guided drug development and precision medicine. The vast dataset will help identify new drug targets, refine clinical trial designs, and improve patient stratification. This positions the corporation to lead the integration of real-world genomic data into personalized healthcare. A pharmacist at work in their online pharmacy checking over orders for pharmaceutical products. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) continues to advance its pipeline with FDA priority reviews for Dupixent (bullous pemphigoid) and Linvoseltamab (multiple myeloma), as well as promising late-stage results for EYLEA HD in eye disorders. The firm's focus remains on leveraging data and science to drive innovative, effective therapies. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-07-2025
- Yahoo
23andMe users have until today to file a claim in the DNA company's bankruptcy case. Here's how to do it.
Today is the deadline for customers of the genetic testing company 23andMe to file a claim as part of a restructuring in its bankruptcy case. In filing a claim, eligible customers can seek compensation for suffering financial or other damages due to a 2023 cyberattack that compromised the sensitive personal information of nearly 7 million users. The direct-to-consumer company has customers submit a saliva sample for their DNA to be analyzed for ancestry purposes, family traits or health risks. 23andMe disclosed the data breach in October 2023, acknowledging that it had exposed users' personal information, including names, relationship labels, ancestry reports and percentage of DNA shared with relatives. This resulted in multiple class-action lawsuits. The DNA testing company filed for Chapter 11 bankruptcy protection in the U.S. in March due to low demand for its ancestry kits in the fallout of the breach. 23andMe alerted customers of the July 14 claim deadline back in May, which was set by the U.S. Bankruptcy Court for the Eastern District of Missouri. There are two types of claims that current and former 23andMe customers can file to receive money back: One is related to cybersecurity (Cyber Security Incident Claim), the other is not cybersecurity-related (General Bar Date Package). Eligible customers can submit either claim by following the instructions on this website. The deadline to file both types of claims is today — Monday, July 14, 2025. If it's submitted electronically, the deadline is at 11:59 p.m. CT; if it's submitted by hard copy, the deadline is 4:59 p.m. CT. Cyber Security Incident Claim 23andMe customers who are eligible to submit the Cyber Security Incident Claim electronically or via postal mail have to meet the following criteria: They were a customer of 23andMe between May 1, 2023, and Oct. 1, 2023. They received a notice that their personal information was compromised in the 2023 data breach. The customer 'incurred monetary damages or non-monetary damages' related to the cybersecurity incident. General Bar Date Package For 23andMe customers who believe they have a claim against the company's services, but it isn't cybersecurity-related, they should file a claim electronically or via postal mail under the General Bar Date Package. This could be related to non-cybersecurity issues, like problems with a customer's DNA results or telehealth services. If a 23andMe customer has questions about the claims process, more information can be found here. Customers can also email 23andMeInfo@ or call (888) 367-7556. No. A Chapter 11 bankruptcy filing means the company is restructuring, instead of liquidating its assets. 23andMe announced at the end of June that it has found a buyer, TTAM Research Institute, which is a nonprofit led by 23andMe cofounder and former CEO Anne Wojcicki. 'The transaction remains subject to Bankruptcy Court approval and customary closing conditions,' the company says. The access that current 23andMe customers have remains unchanged. 'There are no changes to how we store, manage or protect customer data,' according to 23andMe. After filing for Chapter 11 bankruptcy, 23andMe received permission from a judge to sell its most valuable asset — customers' DNA data. 'TTAM has affirmed its commitment to comply with 23andMe's privacy policy and applicable law with respect to treatment of customer data,' the company says, acknowledging the potential sale to TTAM Research Institute. A customer's 23andMe DNA data is not protected under the Health Insurance Portability and Accountability Act, known as HIPAA, which is a law that protects a person's private health information from being shared without the person's knowledge or consent. HIPAA only protects that type of information when it's provided to an entity like a hospital system, physician health plans or billing companies that conduct business with them. 23andMe is not subject to HIPAA regulations because it's a direct-to-consumer company outside of the health care realm. The person is treated as a consumer rather than a patient. The company noted in their FAQ for customers that there's an option for them to delete their data and account. Here's how users can delete their account and personal information: Log into your 23andMe account and go to the 'Settings' section of your profile Scroll to a section labeled '23andMe Data' at the bottom of the page Click 'View' next to '23andMe Data' Scroll to the 'Delete Data' section Click 'Permanently Delete Data' Confirm your request: You'll receive an email from 23andMe; follow the link in the email to confirm your deletion request "If a customer opted in to 23andMe Research, their Personal Information will no longer be used in any future research projects," a 23andMe spokesperson told CNET. "Please note, data cannot be removed from research that's already been conducted."
